Amgen Inc. $AMGN Shares Purchased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. raised its stake in Amgen Inc. (NASDAQ:AMGN) by 6.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,015 shares of the medical research company’s stock after purchasing an additional 1,487 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Amgen were worth $8,334,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Anfield Capital Management LLC lifted its stake in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares in the last quarter. Dogwood Wealth Management LLC increased its position in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Tower View Wealth Management LLC increased its position in Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after purchasing an additional 63 shares in the last quarter. Manning & Napier Advisors LLC raised its holdings in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the period. Finally, Ares Financial Consulting LLC purchased a new position in Amgen in the fourth quarter valued at approximately $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 6,222 shares of company stock worth $2,540,926. Insiders own 0.85% of the company’s stock.

Amgen Price Performance

Shares of AMGN stock opened at $433.73 on Friday. The firm has a fifty day simple moving average of $377.35 and a 200-day simple moving average of $361.40. The company has a market capitalization of $234.49 billion, a PE ratio of 26.96, a price-to-earnings-growth ratio of 4.09 and a beta of 0.41. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $443.20. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter in the previous year, the firm posted $6.02 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.89 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is presently 62.65%.

Analyst Upgrades and Downgrades

AMGN has been the subject of several research reports. Truist Financial boosted their price objective on shares of Amgen from $340.00 to $362.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Wells Fargo & Company lifted their target price on shares of Amgen from $390.00 to $400.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Citigroup upped their price target on shares of Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Cantor Fitzgerald increased their price target on Amgen from $350.00 to $400.00 and gave the company a “neutral” rating in a report on Tuesday. Finally, Scotiabank raised their price objective on Amgen from $385.00 to $450.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $380.43.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Unusually heavy call-option activity points to increased bullish positioning. Investors purchased 79,035 call options, roughly 931% above typical volume, although options activity is speculative and does not guarantee future gains.
• Positive Sentiment: Argus raised its price target from $375 to $460 and upgraded Amgen to “Buy,” adding to the series of favorable analyst views. Argus price target report
• Positive Sentiment: Mizuho and Cantor Fitzgerald analysts also projected further appreciation for Amgen, reinforcing the bullish sentiment around the company’s earnings performance and pipeline. Mizuho Amgen forecast Cantor Fitzgerald Amgen outlook
• Positive Sentiment: Amgen has outperformed several major drugmakers in 2026, attracting investor interest as markets favor profitable pharmaceutical companies even without an obesity-drug franchise. Drugmaker stock performance comparison
• Neutral Sentiment: Biotech ETFs are benefiting from innovation, obesity-drug demand and merger activity, creating a favorable sector backdrop, though the article does not identify a specific new catalyst for Amgen. Biotech ETF growth article
• Negative Sentiment: Industry caution around obesity-drug development is a risk: investors are penalizing undifferentiated programs, and Amgen has reportedly trimmed some early-stage efforts. Obesity drug investment outlook

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.